Lantheus Holdings, Inc. Capital Expenditures Incurred but Not yet Paid
Lantheus Holdings, Inc. (LNTH) reported Capital Expenditures Incurred but Not yet Paid of $2.21 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2026-08-06
- Lantheus Holdings, Inc. capital expenditures incurred but not yet paid for the quarter ending 2026-06-30 was $171.00K, a 82.53% decline year-over-year.
- Lantheus Holdings, Inc. capital expenditures incurred but not yet paid for the quarter ending 2026-03-31 was $2.04M, a 65.23% decline year-over-year.
- Lantheus Holdings, Inc. capital expenditures incurred but not yet paid for the quarter ending 2025-12-31 was -$1.87M.
- Lantheus Holdings, Inc. capital expenditures incurred but not yet paid for the quarter ending 2025-09-30 was -$1.52M, a 368.50% decline year-over-year.
- Lantheus Holdings, Inc. capital expenditures incurred but not yet paid for fiscal 2025 was $3.44M, a 31.89% decline from fiscal 2024.
- Lantheus Holdings, Inc. capital expenditures incurred but not yet paid for fiscal 2024 was $5.06M, a 27.52% decline from fiscal 2023.
- Lantheus Holdings, Inc. capital expenditures incurred but not yet paid for fiscal 2023 was $6.98M, a 194.43% increase from fiscal 2022.
- Lantheus Holdings, Inc. capital expenditures incurred but not yet paid for fiscal 2022 was $2.37M, a 87.80% increase from fiscal 2021.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 9 month | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|---|---|
| 2026-06-30 | $171.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $2.21M 10-Q · filed 2026-08-06 | $335.00K derived: sum of 3 quarters · filed 2026-08-06 | -$1.18M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $2.04M 10-Q · filed 2026-05-07 | $164.00K derived: sum of 2 quarters · filed 2026-05-07 | -$1.35M derived: sum of 3 quarters · filed 2026-05-07 | -$374.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$1.87M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$3.39M derived: sum of 2 quarters · filed 2026-02-26 | -$2.41M derived: sum of 3 quarters · filed 2026-08-06 | $3.44M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$1.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$538.00K derived: sum of 2 quarters · filed 2026-08-06 | $5.32M 10-Q · filed 2025-11-06 | $1.87M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $979.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $6.83M 10-Q · filed 2026-08-06 | $3.39M derived: sum of 3 quarters · filed 2026-08-06 | $3.96M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $5.86M 10-Q · filed 2026-05-07 | $2.41M derived: sum of 2 quarters · filed 2026-05-07 | $2.98M derived: sum of 3 quarters · filed 2026-05-07 | $4.06M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$3.44M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$2.88M derived: sum of 2 quarters · filed 2026-02-26 | -$1.79M derived: sum of 3 quarters · filed 2026-02-26 | $5.06M 10-K · filed 2026-02-26 |
| 2024-09-30 | $565.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $1.65M derived: sum of 2 quarters · filed 2025-11-06 | $8.50M 10-Q · filed 2025-11-06 | $6.91M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $1.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $7.94M 10-Q · filed 2025-08-06 | $6.34M derived: sum of 3 quarters · filed 2026-02-26 | $5.09M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $6.85M 10-Q · filed 2025-05-07 | $5.26M derived: sum of 2 quarters · filed 2026-02-26 | $4.00M derived: sum of 3 quarters · filed 2026-02-26 | $5.39M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | -$1.59M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$2.85M derived: sum of 2 quarters · filed 2026-02-26 | -$1.47M derived: sum of 3 quarters · filed 2026-02-26 | $6.98M 10-K · filed 2026-02-26 |
| 2023-09-30 | -$1.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $130.00K derived: sum of 2 quarters · filed 2024-11-06 | $8.57M 10-Q · filed 2024-11-06 | $8.64M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | $1.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-31 | $9.83M 10-Q · filed 2024-07-31 | $9.89M derived: sum of 3 quarters · filed 2025-02-26 | |
| 2023-03-31 | $8.44M 10-Q · filed 2024-05-02 | $8.51M derived: sum of 2 quarters · filed 2025-02-26 | ||
| 2022-12-31 | $67.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $2.37M 10-K · filed 2025-02-26 | ||
| 2022-09-30 | $2.30M 10-Q · filed 2023-11-02 | |||
| 2021-12-31 | $1.26M 10-K · filed 2024-02-22 | |||
| 2020-12-31 | $2.23M 10-K · filed 2023-02-23 | |||
| 2019-12-31 | $4.17M 10-K · filed 2022-02-24 | |||
| 2018-12-31 | $7.39M 10-K · filed 2021-02-25 | |||
| 2017-12-31 | $2.74M 10-K · filed 2020-02-25 | |||
| 2016-12-31 | $4.99M 10-K · filed 2019-02-20 | |||
| 2015-12-31 | $185.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-26 | -$451.00K derived: sum of 2 quarters · filed 2018-02-26 | $1.13M 10-K · filed 2018-02-26 | |
| 2015-09-30 | -$636.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-04 | $940.00K 10-Q · filed 2015-11-04 | ||
| 2015-06-30 | $1.58M 10-Q · filed 2015-08-05 | |||
| 2014-12-31 | $1.43M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-23 | $1.69M derived: sum of 2 quarters · filed 2017-02-23 | $2.92M 10-K · filed 2017-02-23 | |
| 2014-09-30 | $262.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-04 | $1.49M 10-Q · filed 2015-11-04 | ||
| 2014-06-30 | $1.23M 10-Q · filed 2015-08-05 | |||
| 2013-12-31 | $1.24M 10-K · filed 2016-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B |